| Fiscal Month | 6月 |
|---|---|
| Established | 2000.1 |
| Listed | 2009.9 |
| Headquarters | 410-0801 静岡県沼津市大手町2-2-1 |
| Phone | 055-954-3666 |
| Employees | <25.12> 15名(47.7歳) [年]755万円 |
| URL | https://www.canbas.co.jp/ |
| Bank | みずほ,三菱Ｕ,静岡 |
| Supplier | ― |
| Customer | ― |
| Business Segments | 医薬品100 <25.6> |
| Foreign Ownership | 0.7% |
| Floating Shares | 40.9% |
| Investment Fund | 0.0% |
| Specific Shares | 8.9% |
| Market Cap Ranking | バイオテクノロジー 時価総額順位 22/54社 |
基本情報
抗がん剤開発に特化した創薬ベンチャー。主力の膵臓がん治療薬候補は自社開発。導出も模索
特色【赤字続く】導出一時金など想定せず。開発が最も進む膵臓がん３次治療薬候補ＣＢＰ501は欧州３相治験準備。複数候補の研究開発費先行で営業赤字続く。27年６月期は治験進捗で開発費増え、営業赤字拡大。
【計画】ＣＢＰ501は欧州３相治験申請中、自社で承認まで開発目指す予定。ＣＢＳ9106は開発方針検討。ＣＢＴ005は前臨床試験準備。継続前提に重要事象。
【生産性比較】従業員数＋1人
１人当り営業利益-7,921万円(―倍)
【採用】初‥万円
予‥内定‥(女‥)中途‥
業績・指標・配当
| Period | Type | Revenue(M¥) | Op.Profit(M¥) | Net Income(M¥) | Op.Margin(%) | Net Margin(%) | EPS(¥) | Div(¥) |
|---|---|---|---|---|---|---|---|---|
| 単20.6 | Act | 110 | -566 | -572 | -514.5% | -520.0% | -83.6 | 0 |
| 単21.6 | Act | 108 (-1.8%) | -547 (+3.4%) | -531 (+7.2%) | -506.5% | -491.7% | -70 (+16.3%) | 0 |
| 単22.6 | Act | － | -846 (-54.7%) | -855 (-61.0%) | - | - | -88.3 (-26.1%) | 0 |
| 単23.6 | Act | － | -965 (-14.1%) | -1,244 (-45.5%) | - | - | -83 (+6.0%) | 0 |
| 単24.6 | Act | － | -1,262 (-30.8%) | -1,209 (+2.8%) | - | - | -67.9 (+18.2%) | 0 |
| 単25.6 | Act | － | -1,109 (+12.1%) | -1,157 (+4.3%) | - | - | -61.1 (+10.0%) | 0 |
| 単25.7～12 | Int | － | -600 | -568 | - | - | -28.9 | 0 |
| 単26.6予 | Fcst | 0 | -1,400 (-26.2%) | -1,400 (-21.0%) | - | - | -71.1 (-16.4%) | 0 |
| 単26.7～12予 | Fcst,Int | 0 | -1,000 (-66.7%) | -1,000 (-76.1%) | - | - | -- | -- |
| 単27.6予 | Fcst | 0 | -2,300 (-107.4%) | -2,300 (-98.8%) | - | - | -116.7 (-91.0%) | 0 |
| Period | 単25.6 |
|---|---|
| Total Assets (M¥) | 2,473 |
| Equity (M¥) | 2,342 |
| Equity Ratio | 94.7% |
| Capital (M¥) | 8,467 |
| Retained Earnings (M¥) | -14,579 |
| Interest Bearing Debt (M¥) | 0 |
| ROE | -44.4% 予-59.8% |
| ROA | -37.9% 予-56.6% |
| Operating CF (M¥) | -771 |
| Investing CF (M¥) | 0 |
| Financing CF (M¥) | 1,748 |
| Cash (M¥) | 2,827 |
| CapEx | ･･ 予･･ |
| Depreciation | ･･ 予･･ |
| R&D Expense | 820 予･･ |
| BPS (¥) | 118.9 / 147.8 |
| Period | Amount | Forecast |
|---|---|---|
| 21.6 | 0 | |
| 22.6 | 0 | |
| 23.6 | 0 | |
| 24.6 | 0 | |
| 25.6 | 0 | |
| 26.6予 | 0 | Yes |
| 27.6予 | 0 | Yes |
株主・役員構成
| Name | Shares (Ratio) |
|---|---|
| 楽天証券 | 72(3.6) |
| ＳＢＩ証券 | 13(0.6) |
| 日本証券金融 | 12(0.6) |
| （株）三星住発 | 12(0.6) |
| 安井弘高 | 9(0.4) |
| 河邊拓己 | 8(0.4) |
| 西村彰 | 8(0.4) |
| 安達佳生 | 7(0.3) |
| 大和証券 | 7(0.3) |
| 今村均 | 7(0.3) |
| Title | Name | Outside |
|---|---|---|
| 社長 | 河邊 拓己 | |
| 取締 | 加登住 眞 | |
| 取締 | 坂本 一良 | |
| 取締監査 | 小宮山 靖行 | * |
| 取締監査 | 白川 彰朗 | * |
| 取締監査 | 古田 利雄 | * |
No PDF available for the selected report.
この銘柄のEDINETレポートが見つかりませんでした。